We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

DIAGAST

DIAGAST develops, manufactures and markets reagents and automated systems for blood group determination. Its wide pro... read more Featured Products: More products

Download Mobile App





Diagast Presents Latest Immunohaematology Solutions at MEDLAB Middle East

By LabMedica International staff writers
Posted on 26 Jan 2022
Print article
Image: DIAGAST at MEDLAB Middle East (Photo courtesy of DIAGAST)
Image: DIAGAST at MEDLAB Middle East (Photo courtesy of DIAGAST)

DIAGAST (Loos, France) participated in the 2022 edition of MEDLAB Middle East held at the Dubai World Trade Centre (DWTC) from January 24 to 27 where it presented its latest immunohaematology solutions and also organized a scientific workshop for Blood Transfusion Day.

Blood transfusion is at the heart of healthcare professionals’ concerns. From the donor to the patient, there are many challenges to be met to ensure the compatibility of transfusions. DIAGAST is a worldwide leader in the marketing and development of reagents and instrumentation systems that aim to ensure donor and patient compatibility during blood transfusions. The company develops, manufactures and markets reagents (for blood group determination), miniaturized laboratories for manual analysis and automated systems. DIAGAST offers high performance product ranges and automated systems, guaranteeing the quality of transfusion diagnosis and patient safety.

At MEDLAB Middle East 2022, DIAGAST showcased its QWALYS 3 EVO automated system which is the only fully-automated system on the market using the magnetization of erythrocytes, a process that no longer requires washing and centrifugation steps. DIAGAST’s Erythrocyte Magnetized (EM) technology is based on Red Blood Cells (RBC) magnetization. This innovative solution enables avoiding washing and centrifugation steps usually associated to traditional immunohaematology testing. It uses a patented high-density solution (NanoLys) which creates a barrier that blocks non-specific antibodies which could interfere when performing direct and indirect antiglobulin tests. A latest-generation and fully-automated system with high throughput, large loading capacity and STAT function among others, QWALYS 3 EVO is the benchmark instrument for all laboratories, blood banks, blood transfusion centers and hospitals.

Related Links:
DIAGAST 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Researchers have found a way to spot the debilitating disease Alzheimer\'s before it develops into dementia (Photo courtesy of 123RF)

Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia

Alzheimer’s disease is well known for its slow development over many years, which typically leads to treatment interventions only after the disease has advanced to stages where it may be nearly impossible... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: The new method is quick and easy, and can also be used by non-medical personnel. (Photo courtesy of Zoratto et al. Advanced Science 2024, edited)

New Blood Test Device Modeled on Leeches to Help Diagnose Malaria

Many individuals have a fear of needles, making the experience of having blood drawn from their arm particularly distressing. An alternative method involves taking blood from the fingertip or earlobe,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.